Tumor-Associated Macrophages: Protumoral Macrophages in Inflammatory Tumor Microenvironment

Somaiyeh Malekghasemi1,2, Jafar Majidi1,3, Amir Baghbanzadeh1, Jalal Abdolalizadeh4, Behzad Baradaran2,3,4, Leili Aghebati-Maleki1,2,3,4

1Department of Basic Oncology, Oncology Institute, Hacettepe University, Sihhiye, Ankara, TR-06100, Turkey.
2Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
4Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Keywords:
- Tumor-associated macrophage (TAMs)
- Tumor microenvironment (TME)
- Therapeutic target
- Malignant cells

Abstract
Tumor microenvironment consists of malignant and non-malignant cells. The interaction of these dynamic and different cells is responsible for tumor progression at different levels. The non-malignant cells in TME contain cells such as tumor-associated macrophages (TAMs), cancer associated fibroblasts, pericytes, adipocytes, T cells, B cells, myeloid-derived suppressor cells (MDSCs), tumor-associated neutrophils (TANs), dendritic cells (DCs) and Vascular endothelial cells. TAMs are abundant in most human and murine cancers and their presence are associated with poor prognosis. The major event in tumor microenvironment is macrophage polarization into tumor-suppressive M1 or tumor-promoting M2 types. Although much evidence suggests that TAMs are primarily M2-like macrophages, the mechanism responsible for polarization into M1 and M2 macrophages remain unclear. TAM contributes cancer cell motility, invasion, metastases and angiogenesis. The relationship between TAM and tumor cells lead to used them as a diagnostic marker, therapeutic target and prognosis of cancer. This review presents the origin, polarization, role of TAMs in inflammation, metastasis, immune evasion and angiogenesis as well as they can be used as therapeutic target in variety of cancer cells. It is obvious that additional substantial and preclinical research is needed to support the effectiveness and applicability of this new and promising strategy for cancer treatment.

Introduction
The relationship between cancer and inflammation were observed in the nineteenth century and the most of tumors often occurred in chronic inflammatory sites.1 In fact, inflammatory microenvironment has been identified as an integral component of carcinogenesis.2 The hallmark of tumor-promoting inflammation include the presence of inflammatory cells and inflammatory mediators in the tumor stromal cells. The formation of inflammatory microenvironment mediates by genetic events and immune cells such as regulatory T cells, myeloid-derived suppressor cells (MDSCs), tumor-associated neutrophils (TANs), regulatory B cells and tumor-associated macrophages (TAMs). These heterogeneous cells interact with tumor cells to contribute the tumor initiation, promotion and metastases.3 TAMs are the major component of tumor-associated stromal cells that orchestrated cancer-related inflammation.4 The main features of macrophages are heterogeneity and plasticity in tumor microenvironment and TAMs have either tumor-promoting or prevention role upon different stimuli. Macrophages can be polarized into different phenotypes: classically activated macrophages M1 and alternatively activated macrophages M2 in tumors. M1-like macrophages activated by interferon-γ (IFN-γ) and lipopolysaccharide (LPS) which produced pro-inflammatory cytokines like IL-12, IL-23, TNF-α and IL-6 that promote Th1 responses. In contrast, IL-4, IL-10, IL-13 and TGF-β stimulated M2-like macrophages which induce Th2 responses.5 TAMs enhance tumor angiogenesis, metastases, tissue repair, extracellular matrix (ECM) degradation and suppress immune responses.6 However, the extremely complicated relationship between TAMs and malignant tumor cells remains a subject of controversy. On the other hand, the multifaceted role of TAMs in tumor progression, they are now being as a therapeutic target, diagnostic and prognosis markers for cancer. In this review, we discuss how TAMs mediated tumor progression and we summarized novel molecule and mechanism involved in macrophage polarization and recruitment offers novel therapeutic approaches.

*Corresponding Authors: Leili Aghebati-Maleki, Email: aghebatil@tbzmed.ac.ir, Behzad Baradaran, Email: baradaranb@tbzmed.ac.ir

© 2020 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
Origins of TAMs

The first line of defense mediated by innate immune response like macrophages, which participate in immune responses, tissue repair and homeostasis. Recent studies in pancreatic cancer shows skepticism about the origin of TAMs from hematopoietic stem cells and they proved that TAMs derived from embryonic precursors or primitive yolk sac precursors referred to tissue-resident macrophages with self-renewal capability. Movahedi and colleagues described that two major circulating monocytes, “Ly6C+ inflammatory” or “Ly6C+ resident” monocytes, is the major source of TAM in mice. They injected labeled Ly6C+ and Ly6C− monocytes into tumor-bearing mice. They found that inflammatory monocytes contain TAM precursor cells. A comparative gene expression profiling from murine tumor microenvironment revealed that TIE-2 expression monocytes (TEM) and TAM profiles were related each other. Resident macrophages and TIE-2 embryonic macrophages express a gene signature closely related to circulating TEM. On the other hand, TAMs express a gene profiling more similar to circulating TEM. More over, TAMs show enhanced angiogenic activity with lower pro-inflammatory activity. However, the relationship between TAM and TEM are elusive and additional studies are needed. Metastatic breast cancer patients have elevated level of TEM which monocytes express (CD11b+CD14+CD45+ cells, TIE-2) in their peripheral blood and in the breast tumor microenvironment. In gliomas, TAMs derived from resident microglial cells of embryonic origin, infiltrated blood monocytes and monocyctic M-MDSCs. STAT3 is a key transcription factor induce the polarization of M-MDSCs into mature TAMs. The polarization of mouse inflammatory monocytes (Ly6C+CCR2+cells) into TAMs mediated by a major transcriptional effector of Notch signaling like RBPJ and down regulation of this protein in TAMs reduced the tumor size in mouse breast cancer. Chemoattractants, cytokines such as CSF-1, VEGF, and IL-34, chemokines like CCL2 and CCL5, and complement components (C5a) responsible for recruitment of inflammatory monocytes and monocyctic myeloid-derived suppressor cells (M-MDSCs) into the tumor microenvironment. Indeed, such chemotactic factors activate transcriptional factors that contributes the differentiation of macrophage. The binding of CCL18 to its receptor PITPNM3 recruits macrophages in human breast cancer model with the collaboration of CSF2 mediators. An important player in the recruitment of monocytes to the tumor, is considered CCL2-CCR2 axis that has been proposed as a new therapeutic target. There is controversial debate about the exact origin of CCL2 within tumor. Zhou et al found that TAMs as a main source of CCL2 and CCL17 in HCC, which adsorbed the macrophages and CCR4+ Treg cells to the tumor tissue. In return, Spary et al identified CCL2 derived fibroblasts recruited the monocytes in prostate cancer. On the other hand, CCL2 induce the production of CCL3 in human and murine macrophages, which this CCL3-CCR1 axis promotes metastasis in the mouse model (Figure 1).

Polarization of TAMs

Based on their presence in the tumor microenvironment, TAMs associated with phenotypic plasticity, intratumor and intertumor diversity, ultimately, they polarized toward immunosuppressive phenotype. TAMs characterized as M2-like macrophage, which express surface molecules include CD204 (macrophage scavenger receptor A), CD163, CD206 (MRC1), CD301, stabilin-1 (scavenger receptor and adhesion molecule), dectin-1, DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin), chemokine (such as CCL17, CCL18, CCL22), cytokine (such as IL-10, IL-1ra, decoy IL-1RII), vascular endothelial growth factor (VEGF), arginase I, Fizz1 (resistin-like beta, also known as Fizz1) and Ym1 (chitinase 3-like 3, also known as Ym1). M2-like macrophage polarization induce by IL-4, IL-13, Toll-like receptor and IL-10. MI-like macrophages polarized with (for example, LPS, IFN-γ and TNF-α), usually express high level of HLA-DR, iNOS which produced proinflammatory cytokines like TNF-α, IL-1β, IL-6 and IL-12. TAMs by bidirectional interaction can promote immunosuppressive of regulatory T cells.
TAMs facilitated tumor proliferation and metastasis by production of MMPs, cathepsins, FGE, VEGF, PDGF and various chemokines like CXCL8.26 CSF-1, is a monocyte attractant in TME, which promote tumorigenesis that derive macrophages polarization toward M2-like phenotypes. In contrast, GM-CSF activate antimtumor activity of macrophages.27 In pancreatic ductal adenocarcinoma, cancer-associated fibroblasts in TME produced GM-CSF and induce M2 polarization.28 A recent study showed that the anti-inflammatory lectin REG3β enhanced the polarization of M2-like phenotype in an orthotopic pancreatic cancer of mouse model.29 REG4 another lectin, involved in macrophage polarization toward M2 phenotype in pancreatic cancer by induction of EGFR/AKT/CREB signalling pathway.30 Exosomal miR-30a-3p maintain M2 phenotype during hypoxic condition via activation of PTEN/Pi3Kγ signaling pathway in pancreatic cancer metastasis.31 Biglycan and hyaluronan, Tumor-derived ECM components, induced TAM polarization via TLR2 and TLR4.32 Recently, micro-RNAs as regulator of gene expression could be used as a biomarkers in pathogenesis of cancer and inflammatory diseases. M1 macrophages express miR-125, miR-155 and miR-378 and M2 macrophages upregulated miR-9, miR-146, miR-147, miR-187 and miR-511-3p.33 In particular, miR-155 induce the polarization of macrophages toward M1 phenotype by regulation of NF-κB signaling pathway in response to LPS and IFN-γ.34 Bouhlel et al found that PPAR-γ (peroxisome proliferator-activated receptor gamma) as a type-II nuclear receptor differentiated monocytes toward M2-like macrophages. PPAR-γ express in adipose tissue, colon and macrophages and regulate fatty acid storage and glucose metabolism.35 TLR4 agonist like heat-treated Mycobacterium indicus pranii (Mw) in combination with DTA-1( an agonistic antibody for glucocorticoid-induced TNFR-related protein (GITR)) induce the repolarization of TAMs into M1-like macrophages by a significant increase in IL-12, iNOS and HLA-DR in a mouse model of advanced stage melanoma.36

**TAM functions in tumor microenvironment**

**TAM in inflammation**

The relationship between inflammation and cancer can be classify into two pathways: the intrinsic pathway and the extrinsic pathway. The intrinsic pathway driven by genetic events include the activation of proto-oncogene by mutation, inactivation of tumor-suppressor gene, chromosomal amplification and deletion. The extrinsic pathway is activated by inflammatory conditions at certain anatomical sites (such as colon, pancreas, prostate). The converging of two pathways resulting in the activation of NF-KB transcription factor, HIF-1α and signal transducer and activator of transcription 3 (STAT3) in tumor cells. These transcription factors induce the production of inflammatory cytokines, chemokines as well as prostaglandins. These mediators recruited leukocytes, mostly monocytes, resulting in the production of cancer-related inflammatory microenvironment.37 TAMs are an important leukocyte infiltration in TME that connected inflammation and cancer.38 TAMs in mouse and human tumors have M2 phenotype, which promote tumor progression, angiogenesis, remodeling tissues, metastasis and suppression of adaptive immunity. Signals derived from regulatory T cells and tumor cells like IL-10, TGF-β and M-CSF differentiated M2 phenotype in tumor tissue.39 Cancer related inflammation have dual potential features and may be affected by tissue type. Psoriasis is a chronic inflammatory disease that is not related to an increased risk of skin cancer because it is a T helper1-cell-mediated disease. In some tumor subtypes like eosinophils in colon tumors, TAMs in a subset of breast tumors and pancreatic tumors, the presence of inflammatory cells associated with better prognosis.40 Evidences showed that NF-KB determine protumour and anti-tumour responses in macrophages.41 More recently, patients with bladder cancer treated by administering Mycobacterium bovis bacillus Calmette–Guerin. This treatment induced the polarization macrophages toward M1 phenotype by triggering of TLR receptors.42 Multiple evidence indicated that immune inflammatory cells in neoplasia can be promote tumor progression, angiogenesis and invasion. Necrotic cells can release pro-inflammatory factors, such as IL-1α into tumor microenvironment.5 TAMs promote the survival of inflammatory breast cancer IBC by expression of gene encoding the AXL/GAS6 (growth arrest- specific protein 6) signaling.43 Versican, an extracellular proteoglycan, which activate macrophages via TLR2 and TLR6 in lung cancer. TLR2/6 enhanced LLC metastasis growth by secretion of TNF-α from myeloid cells44 (Figure 2).

**TAM in angiogenesis**

Like healthy tissues, tumors need to create a bloodstream to supply their oxygen and nutrients and other metabolic functions.45 This achieved through angiogenesis, which consists of formation a new blood vessel from circulating endothelial progenitor cells and pre-existing vessels.46 HIF is an important signals regulating angiogenesis process because they transcribed the genes responsible for inducing angiogenesis like vascular endothelial growth factor (VEGF-A). The pro-angiogenesis capacity of TAMs depended on secretion of growth factors and inflammatory cytokines by promoting EC survival, proliferation and activation.47 TAMs are a major source of VEGF-A in mice and human. The elimination of VEGF-A in TAMs hindrance angiogenic switch and weaken the formation of tumor-associated blood vessels in mouse cancer models.48 Another pro-angiogenic factors secreted by TAMs include placental growth factor (PIGF), VEGF-C, IL-1β, IL-6, TNF, CXCL8 (IL-8) and fibroblast growth factor 2.49 TAMs express WNT signaling pathway and the deletion

---

558 | Advanced Pharmaceutical Bulletin, 2020, Volume 10, Issue 4
of WNT7b in TAMs decreased the vascular density in mouse mammary carcinomas. TAMs secrete soluble and membrane-bound proteases that degrade ECM to release the sequestered pro-angiogenic factors. Accordingly, TAMs that express ANGPT receptor TIE2 (also known as TEK) increased the vascular density and metastasis in some tumors.

Hypoxia induce the expression of CXCL12 and ANGPT2 in tumor tissue, which recruited the CXCR4 + TIE2 + TAMs. Genetic deletion of TIE2 block ANGPT2-TIE2 signaling pathway in TAMs, result in decrease angiogenic interaction. Notch signaling in TAMs associated with pathological angiogenesis but the role of this pathway in tumor angiogenesis were not elucidated. TAMs express semaphorins, vascular guidance molecules, which mediate EC survival and migration. TAMs by induction of IL-10 and STAT3/Bcl-2 signaling pathway are able to inhibit breast cancer apoptosis upon paclitaxel treatment.

Wenes and colleague reported that TAM metabolism and REDD1 are as the first potential target for blood vessel formation. Hypoxia induce the expression of regulated in development and DNA damage response 1 (REDD1), which orchestrate the tumor angiogenesis.

Toge et al investigated that TAM counts were increased in renal-cell carcinoma, showing the elevated level of TAM counts and VEGF among angiogenic factors like PyNPase (pyrimidine nucleoside phosphorylase), MVD (factor VIII), CD34 and pTstage.

**TAM in metastasis**

The great majority of cancers arise from epithelial cells, yielding carcinomas. In order to carcinomas cells acquire motility and invasiveness, they undergo alteration of the epithelial–mesenchymal transition. The hallmark of epithelial cells, E-cadherin and cytokeratins, is repressed, while the component of mesenchymal cells, vimentin and N-cadherin, is induced. In general, studies shown that the interaction between TAMs and malignant cell are required for invasion and metastasis. The movement of cancer cells depend on secretion of EGF from TAM and production of CSF-1 from tumor cells. In breast cancer, CSF-1 secreted from tumor cells recruit monocytes from circulation and these cells differentiatied into TAMs, its in turn produced the EGF. Local secretion of EGF stimulate EGF receptor on breast cancer cells, which induce the SOX-2 gene through activation of STAT3 signaling pathway. The expression Wiskott–Aldrich syndrome protein in TAMs induce mammary carcinoma metastasis and invasion by induction of EGF production from macrophages and migration of macrophages toward CSF-1 from cancer cells. Finally, cancer cell derived GM-CSF induce the secretion of CCL18 from mammary TAMs, which trigger integrin clustering in cancer cells and mesenchymal-like phenotype via activation of NF-KB that mediate adherence to the ECM. Metastasis required dissemination of cells from primary tumor, intravasate into lymphatic and blood microvessels, extravasate at distant sites. In breast cancer, invasive isoform, MENA26, cancer cells and TAMs migrate toward blood vessels by EGF-CSF1 paracrine loop. Mena-overexpressing tumor cell, proangiogenic TIE2/VEGFR macrophage and the endothelial cell make TMEM (tumor microenvironment of metastasis). A unique population of monocytes in pritumoural stroma of HCC express c-Met molecule, which associated with poor survival of patients. These monocytes produced MMP-9 in response to the HGF derived tumor stromal. Macrophages that support metastatic of cancer cells express surface markers like VEGFR1, CCR2, and CX3CR1, which different from angiogenic macrophages express molecules (such as TIE2 or CXCR4). Recent studies demonstrated that CCR2 trigger the production of CCL3 from macrophages in breast cancer mouse model. CCL3 via CCR1 signaling promote metastasis in lung and breast cancer. Recent studies indicated that hypoxic mammary tumors secret lysyl oxidase (LOX) to recruit CD11b+ myeloid cell at metastasis sites and these cells produce MMP-2 to disport collagen IV in experimental breast cancer metastasis models. Additionally, the elimination of LOX prevent metastasis burden into pulmonary.

**TAM in immune evasion**

Immune system plays an important role in eradicating formation of incipient neoplasias and micrometastasis, but solid tumors managed to avoid detection. TAMs derived CCL17, CCL18 and CCL22 adsorbed Treg to tumor stroma, which result in the promoting of immunosuppressive activity of regulatory T cells by immunosuppressive cytokines, including IL-10 and TGFβ. Indoleamine 2, 3-dioxygenase in the tumor microenvironment and TAM breakdown tryptophan, which result in the suppression of T cell and dendritic cell activity. Prostaglandins like COX-1 and COX-2 in
TAMs have immunosuppressive effects on T cells. Tam and PD-L1 to be expressed in TAMs and tumor cells, which promote the inhibitory function of PD-L1. A 'don't eat me' signal that suppress innate immunity through phagocytic activity of macrophage and PD-L1 inhibit adaptive immune responses. In pancreatic cancer, infiltrating Treg in tumor microenvironment upregulated CTLA-4 (cytotoxic T-lymphocyte antigen 4) and PD-1, thus, blockage of these pathways enhance antitumor immunity. TAMs with CD120a, CD120b secret NO, resulting in promoting the apoptosis of activated T cells in tumor tissue. In pancreatic cancer, CD11b+ myeloid cells inhibit CD8+ T cells by induction of PD-L1 in tumor cells in an epidermal growth factor receptor (EGFR)/mitogen-activated protein kinases-dependent manner. TAM derived TGF-β reduced dendritic cells migration, antigen presentation and adaptive immune responses. Recent studies indicated that TAMs trigger CD27low CD11bhigh exhausted NK-cell phenotype and inhibit cytolytic activity of NK cells by TGF-β dependent manner. Additionally, hypoxia promote TAM derived CCL20 via activation of NF-KB signaling pathway. CCL20 induce the recruitment of Va24-invariant NKT cells to the hypoxic TME, where the antitumor function and viability of NKT cells were repressed. TAMs produce CCL2 which induce CCR2+ monocytic MDSCs migration from bone marrow to tumor. However, tumor infiltrating MDSCs polarized toward TAM by CSF-1 and HIF-1α. In human glioblastoma, elevated level of CCL2 correlated with increased counts of TAMs and reduced survival of patient.

**TAM in therapeutic target in cancer**

TAM- targeting immunotherapy represent an effective strategy for cancer treatment. These immunotherapeutic strategies include interference with TAM survival, limiting of macrophage recruitment, targeting TAMs with radiotherapy and reprogramming of tumor-promoting M2- like TAMs to antitumor macrophages (Figure 3).

**Interference with TAM survival**

Trabectedin (ET-743) induce apoptosis in monocytes. This function mediated by activation of caspase-8, which plays pivotal role in the extrinsic apoptotic signaling pathway via Fas and TNF-related apoptosis inducing ligand receptors. Liposome-encapsulated bisphosphonate clodronate can be phagocytized by macrophages leads to macrophages deletion and inhibit tumor progression. In contrast, liposomal trabectedin induce the apoptosis of all macrophages by activation of caspase-8. M2pep target specially with high affinity for M2-like macrophages in murine and subsequently improve the survival of tumor-bearing mouse. Legumain express in TAM in murine breast cancer tissue. A legumain-based DNA vaccine promote the activation of CD8+ T cells and override M2-like macrophage in the metastasis of breast, colon and lung in mice. An RNA aptamer activate CD8+ T cells by targeting murine or human IL4Ra/CD124 on TAMs. IL-27 induce the apoptosis of M2-like macrophages and proliferation, invasion of pancreatic cells. It is also as a novel therapy when combine with gemcitabine and both of them target TAMs in pancreatic cancer.

**Limiting of macrophage recruitment**

CCL2 synthesis by tumor cells, stromal and bone marrow osteoblasts, subsequently mediate tumorigenesis, metastasis and recruitment of inflammatory monocytes that express CCL2 receptor CCR2 to the tumor sites. Blockage of CCL2 and CCR2 suppresses M2 macrophage migration. A CCL2 blockage agent (anti-human CNTO888, carlumab and anti-mouse C1142) in combination with docetaxel induce tumor regression in prostate cancer. A CCR2 kinase antagonist PF-04136309 inhibit M2 macrophage migration in murine pancreatic cancer. CSF1-CSF1R regulate macrophage recruitment, proliferation and differentiation. A CSF1R inhibitors PLX6134, GW2580 and PLX3397 inhibit TAM infiltration by induction of CD8+ T cells activity. Additionally, the monoclonal antibody (mAb) RG7155 against CSF1R reduce TAM recruitment. The CSF1R inhibitor BLZ945 reduced M2-associated genes such as arginase 1 and CD206 in a mouse proneural glioblastoma model. BLZ945 inhibit the activity and proliferation TAMs and reprogramme tumor promoting TAMs to antitumor macrophages.
Reprogramming of M2-like TAMs to M1-like phenotype

Repolarization of M2-like macrophages to anti-tumor phenotype under physiological conditions is a crucial strategy for cancer therapy. In Lewis lung carcinoma mice model tumor, introduction of polyinosinic:polycytidylic acid (polyI:C) into mice activates the TLR3/Toll-like receptor, which reprogrammed M2-like macrophage toward tumor suppressor phenotypes. Inattenuated Listeria monocytogenes into the tumor stroma of ovarian cancer mice model induce tumor cell lysis through synthesis of nitric oxide, resulting in the switch of TAM toward antitumor phenotypes. Similarly, in B16F10 melanoma tumors, introduces of heat-killed Mycobacterium indicus pranii in TME induce the repolarization of M2-like phenotype into M1 macrophages. In spontaneous mammary carcinogenesis, the anti-angiogenic agent like zoledronic acid induce reprogramming of pro-angiogenic TAMs toward tumor suppressor phenotype by vascular normalization. The STAT3 phosphorylation inhibitor such as hydrazinocurcumin switch M2-like phenotype to an M1-like phenotype to inhibit angiogenesis and metastasis in breast cancer. In mouse models of non-small-cell lung cancer, 5, 6-dimethylxanthenone-4-acetic acid switch TAM into M1-like phenotype by promoting the vascular disrupting via STING Activation. In gastric carcinoma progression in mice, Pseudomonas aeruginosa strain (PA-MSHA) induce the switch of M2-like phenotype toward M1 macrophages upon activation of NF-KB signaling pathway. Introduction of anti-CD40 in spontaneously develop pancreatic ductal adenocarcinoma in KPC mice promote the polarization of TAMs toward M1-phenotypes upon activation of IL12, TNFa and INF-γ.

Targeting of TAM with radiotherapy

Radiotherapy is used for treatment of more than 50% cancer patient and associated with tumor regression in majority of cancers. However, macrophages have radiosensitivity property because of having a manganese superoxide dismutase, ROS, RNS and a scavenger of superoxide ions. On the other hand, RT can induce the recruitment of macrophages into the tumor tissue by stimulation of CCL2, CSF1 production and promote the tumor progression. Depletion of macrophages by liposomal clodronate before IR and the inhibition of CSF1 receptor with PLX3397 can promote the anti-tumor effect of RT. Crittenden and his colleagues reported that high doses of irradiation produce M2 phenotype through p50–p50 NFκB homodimer activation and IL-10 production. Similarly, low doses of irradiation reduce the translocation of p50–p65 NFκB into nucleus in M1 macrophages. Moderate doses of irradiation shift macrophages toward M1 phenotype by the activation of NF-κB p65.

Conclusion

Monocyte-macrophage lineage an important component of TME has been identified as a crucial factor in the proliferation and cancer cell progression. Monocytes can be recruited into tumor sites by chemotactic factors, which produce from tumor cells and tumor stroma. Monocytes transformed into M2-like TAM to facilitate tumor angiogenesis, invasion and metastasis. These distinctive phenotype derived from the plasticity nature of macrophages in the tumor microenvironment. TAMs to apply clinically, as a diagnosis and prognosis marker and a therapeutic target as well. Anti-tumor therapeutic strategy include reducing TAM survival, limiting macrophage recruitment and skewing M2-like TAMs into an M1-like phenotype. Among these strategies, switching TAM toward M1 macrophages is most promising because these therapies do not destroy macrophages also can be useful method for tumoricidal activity in the tumor tissue to reduce tumor progression. Recent study identify that TLR ligands promote repolarization of macrophage in mouse models. Additionally, combination of TAM repolarization with checkpoint inhibitors (PD1 or CTLA4 antagonists), stimulating antibodies (CD40 or GITR agonists) and radiotherapy displayed a remarkable strategies for cancer treatment. Vessel normalization susceptible tumor cells to chemotherapy agents. Anti-VEGF and anti-angiopoietin treatment leading to vessel normalization, reduce hypoxia, induce TAM repolarization and improve CTL, NK cell infiltration. Several drugs are used clinically targeting TAM such as trabectedin reduce TAM survival and alemtuzumab eliminates TAMs by targeting a TAM surface protein. Therefore, more investigation are required to assess the elevated ratio of M1-like macrophage to M2-like macrophage to identify tumor prognosis and prevent tumor progression. In addition, TAM population associated with poor prognosis in patient, well-define criteria are essential to evaluated macrophage population.

Ethical Issues

Not applicable.

Conflict of Interest

Authors declare no conflict of interest.

Acknowledgments

This work was supported financially by Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

References

1. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science 2013;339(6177):286-91. doi: 10.1126/science.1232227
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013
3. Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 2016;9:8. doi: 10.1186/s13045-015-0231-4
Malekghasemi et al

4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med* 2013;19(11):1423–37. doi: 10.1038/nm.3394

5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* 2010;140(6):883–99. doi: 10.1016/j.cell.2010.01.025

6. Zhu L, Yang T, Li L, Sun L, Hou Y, Hu X, et al. Tsc1 controls macrophage polarization to prevent inflammatory disease. *Nat Commun* 2014;5:4696. doi: 10.1038/ncomms5696

7. Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG, et al. Induced expression of B7-H1 on the surface of lung cancer cell by the tumor-associated macropahages: a potential mechanism of immune escape. *Cancer Lett* 2012;317(1):99–105. doi: 10.1016/j.canlet.2011.11.017

8. Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. *Immunity* 2017;47(2):323–38.e6. doi: 10.1016/j.immuni.2017.07.014

9. MacDonald MP, Palmer JS, Cronau S, Seppanen E, Oliver S, Raffelt NC, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of macrophages and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood* 2010;116(19):3955–63. doi: 10.1182/blood-2010-02-262966

10. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6c(high) monocytes. *Cancer Res* 2010;70(14):5726–39. doi: 10.1158/0008-5472.CAN-09-4672

11. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguishing gene signature shared by tumor-infiltrating TIE2-expressing monocytes, blood ‘resident’ monocytes, and embryonic macrophages suggests common functions and developmental relationships. *Blood* 2009;114(4):901–14. doi: 10.1182/blood-2009-01-200931

12. Bron S, Henry L, Faes-Van't Hull E, Turrini R, Vanhecke D, Guex N, et al. TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. *Oncoimmunology* 2016;5(2):e1073882. doi: 10.1080/2162402x.2015.1073882

13. Feng X, Szulzewsky F, Yerevanian A, Chen Z, Heinemann R, Rasmussen RD, et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. *Oncotarget* 2015;6(17):15077–94. doi: 10.18632/oncotarget.3730

14. Kumar V, Cheng F, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. CD45 phosphate inhibits stat3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. *Immunity* 2016;44(2):303–15. doi: 10.1016/j.immuni.2016.01.014

15. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. *Science* 2014;344(6186):921–5. doi: 10.1126/science.1252510

16. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* 2005;7(3):211–7. doi: 10.1016/j.ccr.2005.02.013

17. Su S, Liu Q, Chen J, Chen J, Chen F, He C, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. *Cancer Cell* 2014;25(5):605–20. doi: 10.1016/j.ccr.2014.03.021

18. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. *Gut* 2017;66(1):157–67. doi: 10.1136/gutjnl-2015-310514

19. Zhou SL, Zhou ZJ, Hu ZZ, Huang XW, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and t-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. *Gastroenterology* 2016;150(7):1646–58.e17. doi: 10.1053/j.gastro.2016.02.040

20. Spary JK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+PD-L1+ phenotype in prostate cancer. *Oncoimmunology* 2014;3(9):e955311. doi: 10.4161/21624011.2014.955311

21. Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. *J Exp Med* 2015;212(7):1043–59. doi: 10.1084/jem.20141836

22. Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, et al. Dual prognostic significance of tumor-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. *Gut* 2016;65(10):1710–20. doi: 10.1136/gutjnl-2015-309193

23. Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundstrom J, Salmi M, et al. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. *Int J Cancer* 2012;131(4):864–73. doi: 10.1002/ijc.26457

24. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. *Br J Cancer* 2013;108(4):914–23. doi: 10.1038/bjc.2013.32

25. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat Immunol* 2010;11(8):889–96. doi: 10.1038/ni.1937

26. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. *Cell* 2010;141(1):52–67. doi: 10.1016/j.cell.2010.03.015

27. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdert S, et al. Macrophage activation and polarization: Nomenclature and experimental guidelines. *Immunity* 2014;41(1):14–20. doi: 10.1016/j.immuni.2014.06.008

28. Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, et al. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. *Cancer Med* 2017;6(2):463–70. doi: 10.1002/cam4.993

29. Giorella M, Calvo C, Fernandez A, Closa D, Iovanna JL, Rosello-Catafau J, et al. Reg3β deficiency impairs pancreatic tumor growth by skewing macrophage polarization. *Cancer Res* 2013;73(18):5682–94. doi: 10.1158/0008-5472.CAN-12-3057

30. Ma X, Wu D, Zhou S, Wan F, Liu H, Xu X, et al. The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR/AKT/CREB pathway. *Oncol Rep* 2016;35(1):189–96. doi: 10.3892/or.2015.4357

31. Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T, et al.}
TAM in inflammatory tumor microenvironment

32. Sorokin L. The impact of the extracellular matrix on inflammation. *Nat Rev Immunol* 2010;10(10):712-23. doi: 10.1038/nri2852

33. Squadrillo ML, Eztroutd M, De Palma M, Pittet MJ. Microtubula-mediated control of macrophages and its implications for cancer. *Trends Immunol* 2013;34(7):350-9. doi: 10.1016/j.ti.2013.02.003

34. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang CY, et al. Re-polarization of tumor-associated macrophages to macrophages by microrna-155. *J Mol Cell Biol* 2012;4(5):341-3. doi: 10.1093/jmcb/mjs044

35. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. Ppargamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. *Cell Metab* 2007;6(2):137-43. doi: 10.1016/j.cmet.2007.06.010

36. Banerjee S, Halder K, Ghosh S, Bose A, Majumdar S. The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regresses advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ. *Oncosimmunology* 2015;4(3):e995559. doi: 10.1080/2162402x.2014.995559

37. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008;454(7203):436-44. doi: 10.1038/nature06903

38. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampolesi M, et al. TIE2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell* 2005;8(3):211-26. doi: 10.1016/j.ccr.2005.08.002

39. Mantovani A, Sozanni S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized m2 mononuclear phagocytes. *Trends Immunol* 2002;23(11):549-55.

40. Mantovani A, Bottazzi B, Coletta F, Sozanni S, Ruco L. The origin and function of tumor-associated macrophages. *Inmunol Today* 1992;13(7):265-70. doi: 10.1016/0167-5699(92)90008-u

41. Hagemann T, Lawrence T, McNieish I, Charles KA, Kulbe H, Thompson RG, et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. *Exp Med* 2008;205(6):1261-8. doi: 10.1084/jem.20080108

42. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nat Med* 2007;13(9):1050-9. doi: 10.1038/nm1622

43. Sica A. Macrophages give gas(6) to cancer. *Blood* 2010;115(11):2212-3. doi: 10.1182/blood-2009-12-255869

44. Kaplan RN, Ribd RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. Vegfr1L-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005;438(7069):820-7. doi: 10.1038/nature04186

45. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. *Cell* 2011;146(6):873-87. doi: 10.1016/j.cell.2011.08.039

46. Carmeliet P. Angiogenesis in health and disease. *Nat Med* 2003;9(6):653-60. doi: 10.1038/nm0603-653

47. Baer C, Squadrillo ML, Iruela-Arispe ML, De Palma M. Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. *Exp Cell Res* 2013;319(11):1626-34. doi: 10.1016/j.yexcr.2013.03.026

48. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. *Nature* 2008;456(7223):814-8. doi: 10.1038/nature07445

49. Squadrillo ML, De Palma M. Macrophage regulation of tumor angiogenesis: Implications for cancer therapy. *Mol Aspects Med* 2011;32(2):123-45. doi: 10.1016/j.mam.2011.04.005

50. Yeo EJ, Cassetta L, Qian BZ, Lewkowich I, Li JF, Stefater JA 3rd, et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. *Cancer Res* 2014;74(11):2962-73. doi: 10.11180008-5472.Can-13-2421

51. Egeland M, Nakasones ES, Werb Z. Tumors as organs: Complex tissues that interface with the entire organism. *Dev Cell* 2010;18(6):884-901. doi: 10.1016/j.devcel.2010.05.012

52. Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, et al. TIE2-expressing monocytes as a diagnostic marker for hepatoportal carcinoma correlates with angiogenesis. *Hepatology* 2013;57(4):1416-25. doi: 10.1002/hep.25965

53. Welford AJ, Rizziad D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. *J Clin Invest* 2011;121(5):1969-73. doi: 10.1172/JCI44562

54. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. *Cancer Cell* 2011;19(4):512-26. doi: 10.1016/j.ccr.2011.02.005

55. Dou GR, Li N, Chang TF, Zhang P, Gao X, Yan XC, et al. Myeloid-specific blockade of notch signaling attenuates choroidal neovascularization through compromised macrophage infiltration and polarization in mice. *Sci Rep* 2016;6:28617. doi: 10.1038/srep28617

56. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. *Cancer Cell* 2012;22(2):145-52. doi: 10.1016/j.ccr.2012.06.031

57. Yang C, He L, He P, Liu Y, Wang W, He Y, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. *Med Oncol* 2015;32(2):352. doi: 10.20517/sido32-014-0352-6

58. Casazza A, Laoui D, Wenes M, Rizzoli S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. *Cancer Cell* 2013;24(6):695-709. doi: 10.1016/j.ccr.2013.11.007

59. Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages. *Int J Urol* 2009;16(10):801-7. doi: 10.1111/j.1242-2042.2009.02377.x

60. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley

Advanced Pharmaceutical Bulletin, 2020, Volume 10, Issue 4 | 563
ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007;67(6):2649-56. doi: 10.1158/0008-5472.Can-06-1823

61. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65(12):5278-83. doi: 10.1158/0008-5472.Can-04-1853

62. Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGF/Stat3/Sox-2 signaling pathway. Stem Cells 2013;31(2):248-58. doi: 10.1002/stem.1281

63. Ishihara D, Dovas A, Hernandez L, Pozzuto M, Wyckoff J, Sagell JE, et al. Wiskott-aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis. Cell Rep 2013;4(3):429-36. doi: 10.1016/j.celrep.2013.07.007

64. Chen J, Yao Y, Gong C, Yu F, Su S, Chen I, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via pitpnm3. Cancer Cell 2011;19(4):541-55. doi: 10.1016/j.ccr.2011.02.006

65. Pignatelii J, Goswami S, Jones JG, Rohan TE, Pieri E, Chen X, et al. Invasive breast carcinoma cells from patients exhibit menin-v and macrophage-dependent transendothelial migration. Sci Signal 2014;7(353):ra112. doi: 10.1126/scisignal.2005329

66. Zhao L, Wu Y, Xie XD, Chu YF, Li JQ, Zheng L. C-met identifies a population of matrix metalloproteinase 9-producing monocytcs in peritumoral stroma of hepatocellular carcinoma. J Pathol 2015;237(3):319-29. doi: 10.1002/path.4578

67. Erler JT, Bennewich KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15(1):35-44. doi: 10.1016/j.ccr.2008.11.012

68. Ruffell B, Affara NJ, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012;33(3):119-26. doi: 10.1016/j.it.2011.12.001

69. Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity 2015;43(3):435-49. doi: 10.1016/j.immuni.2015.09.001

70. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011;208(3):577-92. doi: 10.1084/jem.20100619

71. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016;352(6282):227-31. doi: 10.1126/science.aad9935

72. D’Alincourt Salazar M, Manuel ER, Taiw S, D’Apuzzo M, Goldstein L, Blazar BR, et al. Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD-1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology 2016;5(6):e1160184. doi: 10.1080/2162402x.2016.1160184

73. Saio M, Radoja S, Marino M, Frey AB. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+)* T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol 2001;167(10):5583-93. doi: 10.4049/jimmunol.167.10.5583

74. Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, et al. Myeloid cells are required for PD-1/ PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 2017;66(1):124-36. doi: 10.1136/gutjnl-2016-312078

75. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, Nakagawa T, et al. umor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006;176(9):5637-43. doi: 10.4049/jimmunol.176.9.5637

76. Liu D, Song L, Wei J, Courtneyn AN, Gao X, Marinova E, et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antitumour activity. J Clin Invest 2012;122(6):2221-33. doi: 10.1172/jci59535

77. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res 2016;76(19):5671-82. doi: 10.1158/0008-5472.Can-16-0144

78. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Ligouri M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008

79. Zeisermer BM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmo-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006;95(3):272-81. doi: 10.1038/sj.bjc.6603240

80. Cieslewicz M, Tang J, Yu J, Cao H, Zavaljevski M, Motoyaama K, et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A 2013;110(40):15919-24. doi: 10.1073/pnas.1312197110

81. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006;116(8):2132-41. doi: 10.1172/jci27648

82. Roth F, De La Fuente AG, Vella JL, Zosso A, Inverardi L, Serafini P. Aptamer-mediated blockade of il4ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012;72(6):1373-83. doi: 10.1158/0008-5472.Can-11-2772

83. Yao L, Wang M, Niu Z, Liu Q, Gao X, Zhou L, et al. Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages. Cytokine 2018;97:194-200. doi: 10.1016/j.cyt.2015.12.003

84. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 2013;19(13):3404-15. doi: 10.1158/1078-0432.Ccr-13-0525

85. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004;64(15):5378-84. doi: 10.1158/0008-5472.CAN-04-0961

86. Pynteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters...
macrophage polarization and blocks glioma progression. *Nat Med* 2013;19(10):1264-72. doi: 10.1038/nm.3337
87. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. *Proc Natl Acad Sci U S A* 2012;109(6):2066-71. doi: 10.1073/pnas.1113099109
88. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature* 2011;475(7355):222-5. doi: 10.1038/nature10138
89. Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2’3’-cGAMP, induces M2 macrophage repolarization. *PLoS One* 2014;9(6):e99988. doi: 10.1371/journal.pone.0099988
90. Zhang X, Tian W, Cai X, Wang X, Dang W, Tang H, et al. Hydrazinocurcumin encapsulated nanoparticles “re-educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following stat3 suppression. *PLoS One* 2013;8(6):e65896. doi: 10.1371/journal.pone.0065896
91. Downey CM, Aghaei M, Schwendener RA, Jirik FR. Dmxaa causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide sting agonist, 2’3’-cGAMP, induces m2 macrophage repolarization. *PLoS One* 2014;9(6):e99988-e. doi: 10.1371/journal.pone.0099988
92. Wang C, Hu Z, Zhu Z, Zhang X, Wei Z, Zhang Y, et al. The msha strain of pseudomonas aeruginosa (PA-MSHA) inhibits gastric carcinoma progression by inducing m1 macrophage polarization. *Tumour Biol* 2016;37(5):6913-21. doi: 10.1007/s13277-015-4451-6
93. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science* 2011;331(6024):1612-6. doi: 10.1126/science.1198443
94. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. Csf1r signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. *Cancer Res* 2013;73(9):2782-94. doi: 10.1158/0008-5472.CAN-12-3981
95. Wunderlich R, Ernst A, Rodel F, Fietkau R, Ott O, Lauber K, et al. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. *Clin Exp Immunol* 2015;179(1):50-61. doi: 10.1111/cei.12344
96. Rodeck CR, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. *Nat Biomed Eng* 2018;2:578-88.
97. Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. *Immunology* 2011;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x
98. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. *Proc Natl Acad Sci U S A* 2012;109(43):17561-6. doi: 10.1073/pnas.1215397109
99. Pulaski HL, Schahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. *J Transl Med* 2009;7:49. doi: 10.1186/1479-5876-7-49